Gyre Therapeutics Q2 2023 Earnings Report

Gyre Therapeutics EPS Results

• Actual EPS: -$1.05
• Consensus EPS: -$1.05
• Beat/Miss: Met Expectations
• One Year Ago EPS: N/A

Gyre Therapeutics Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Gyre Therapeutics Announcement Details

• Quarter: Q2 2023
• Date: 8/14/2023
• Time: N/A

Gyre Therapeutics (NASDAQ:GYRE), a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.